In a similar way, Alvespimycin and Celastrol reduce bulk and sorted CD34+CD19+, CD34+CD19−, and CD34+ cells from B-ALL primary samples [25], highlighting a potential therapeutic use since these compounds do not show a toxic effect in normal cord blood or HSC. This evidence concerns the gene CD19 and precursor B-cell acute lymphoblastic leukemia.